AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell (OCC) achieves initial sales of Remplir™ in Singapore.
- Expansion into Singapore positions the product in the ASEAN region's nerve repair market.
- Regulatory filings for US FDA clearance set to accelerate growth globally.
Orthocell (ASX:OCC) has reached a pivotal moment in the commercial journey of its innovative nerve repair device, Remplir™, with the product now achieving its first sales in Singapore. This milestone follows regulatory approval granted in October and marks a significant step forward in the company’s efforts to expand its global presence in the advanced medical device market.
The launch in Singapore comes as part of Orthocell’s strategic plan to target regions known for their advancements in healthcare and regulatory influence. The ASEAN region is particularly important, serving as a gateway to broader Southeast Asian markets. The nerve repair device market, globally valued at over US$3.5 billion, presents ample opportunity for growth as Remplir™ gains traction among medical professionals.
The sales were facilitated by Device Technologies Asia (DT Asia), Orthocell’s exclusive distribution partner for the region. DT Asia has played an active role in promoting Remplir™, engaging with healthcare providers and surgeons to highlight the product’s unique repair capabilities. These efforts have also included educational initiatives aimed at raising awareness among plastic and orthopedic surgeons about the benefits of Remplir™ in peripheral nerve repair.
Currently, Remplir™ is available in Singapore, Australia, and New Zealand, where it has already garnered endorsements from surgeons for its ability to provide superior outcomes in nerve repair procedures. Singapore’s advanced healthcare ecosystem and its status as a regulatory hub make it an ideal market for Remplir™, setting the stage for further regional expansion.
Orthocell (OCC) is financially well-positioned to drive growth, boasting $33 million in cash reserves and no debt. The company is focusing on expanding into additional markets, including the US, Canada, the EU, and the UK. Progress in regulatory processes remains a priority, with Orthocell on track to submit a 510(K) application to the US FDA this quarter. If successful, this could pave the way for regulatory clearance and subsequent commercial distribution in the US market, further boosting sales and revenue.
Orthocell’s strides in Singapore signify a promising beginning to the company’s long-term vision of establishing Remplir™ as a leading solution in the global nerve repair market. With strong financial backing and a clear growth strategy, Orthocell is well-placed to build on its recent achievements.
